



# TMT-Based Quantitative Proteomic Analysis Reveals the Effect of Bone Marrow Derived Mesenchymal Stem Cell on Hair Follicle Regeneration

Chao Zhang<sup>1,2,3</sup>, YuanHong Li<sup>1,2,3</sup>, Jie Qin<sup>1,2,3</sup>, ChengQian Yu<sup>1,2,3</sup>, Gang Ma<sup>4</sup>, HongDuo Chen<sup>1,2,3\*</sup> and XueGang Xu<sup>1,2,3\*</sup>

<sup>1</sup>Department of Dermatology, The First Hospital of China Medical University, Shenyang, China, <sup>2</sup>NHC Key Laboratory of Immunodermatology (China Medical University), Shenyang, China, <sup>3</sup>Key Laboratory of Immunodermatology (China Medical University), Ministry of Education, Shenyang, China, <sup>4</sup>Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, China

## OPEN ACCESS

### Edited by:

Zhouguang Wang,  
Albert Einstein College of Medicine,  
New York, NY, United States

### Reviewed by:

Xiaohua Lei,  
Chinese Academy of Sciences,  
Shenzhen, China  
Jian Zhong,  
Shanghai Ocean University, China

### \*Correspondence:

XueGang Xu  
xuxuegang2749290@163.com  
HongDuo Chen  
hongduochen@hotmail.com

### Specialty section:

This article was submitted to  
Integrative and Regenerative  
Pharmacology,  
a section of the journal  
Frontiers in Pharmacology

**Received:** 25 January 2021

**Accepted:** 12 March 2021

**Published:** 14 June 2021

### Citation:

Zhang C, Li Y, Qin J, Yu C, Ma G, Chen H and Xu X (2021) TMT-Based Quantitative Proteomic Analysis Reveals the Effect of Bone Marrow Derived Mesenchymal Stem Cell on Hair Follicle Regeneration. *Front. Pharmacol.* 12:658040. doi: 10.3389/fphar.2021.658040

Hair loss (HL) is a common chronic problem of poorly defined etiology. Herein, we explored the functionality of bone marrow-derived mesenchymal stem cell (BMSC) and conditioned medium (MSC-CM) as regulators of hair follicle proliferation and regeneration, and the mechanistic basis for such activity. BMSC were cultured and identified *in vitro* through the induction of multilineage differentiation and the use of a CCK-8 kit. The dorsal skin of mice was then injected with BMSC and MSC-CM, and the impact of these injections on hair cycle transition and hair follicle stem cell (HFSC) proliferation was then evaluated via hematoxylin and eosin (H&E) staining and immunofluorescent (IF) staining. We then conducted a tandem mass tags (TMT)-based quantitative proteomic analysis of control mice and mice treated with BMSC or MSC-CM to identify differentially expressed proteins (DEPs) associated with these treatments. Parallel reaction monitoring (PRM) was utilized as a means of verifying our proteomic analysis results. Herein, we found that BMSC and MSC-CM injection resulted in the transition of telogen hair follicles to anagen hair follicles, and we observed the enhanced proliferation of HFSCs positive for Krt15 and Sox9. Our TMT analyses identified 1,060 and 770 DEPs (fold change > 1.2 or < 0.83 and  $p < 0.05$ ) when comparing the BMSC vs. control and MSC-CM vs. control groups, respectively. Subsequent PRM validation of 14 selected DEPs confirmed these findings, and led to the identification of *Stmn1*, *Ncapd2*, *Krt25*, and *Ctps1* as hub DEPs in a protein-protein interaction network. Together, these data suggest that BMSC and MSC-CM treatment can promote the proliferation of HFSCs, thereby facilitating hair follicle regeneration. Our proteomics analyses further indicate that *Krt25*, *Cpm*, *Stmn1*, and *Mb* may play central roles in hair follicle transition in this context and may represent viable clinical targets for the treatment of HL.

**Keywords:** bone marrow-derived mesenchymal stem cell, hair follicle stem cell, hair follicle regeneration, TMT-based quantitative proteomics analysis, parallel reaction monitoring

## INTRODUCTION

Hair loss (HL) is a common cosmetic condition that can have a significant adverse impact on the quality of life (QOL) and well-being of affected individuals. Hair follicles function as miniature organs, and are generally relatively synchronous, undergoing three primary stages of growth: a growth (anagen) phase, a rest (telogen) phase, and an apoptosis-mediated regression (catagen) stage (Paus, 1998). Aside from scar tissue- or wound-induced alopecia, the majority of HL-related disorders are attributable to aberrant hair follicle morphology or dysregulating cycling, including the shortening of the anagen stage or the prolongation of the telogen stage (Cotsarelis and Millar, 2001; Varothai and Bergfeld, 2014).

Hair follicle stem cells (HFSCs) are essential for the regeneration of hair follicles and the transition of these follicles from the telogen to anagen stage. These HFSCs exist as a small cellular subpopulation within the midportion of the follicle at the arrector pili muscle attachment site (Cotsarelis et al., 1990; Blanpain et al., 2004), and can be identified at the molecular level owing to their staining for Krt15 (Lyle et al., 1998; Liu et al., 2003) and Sox9 (Vidal et al., 2005; Nowak et al., 2008; Chacón-Martínez et al., 2017).

Bone marrow-derived mesenchymal stem cells (BMSC) are multipotent stem cells (Friedenstein et al., 1974), and they can be readily obtained, grown, and expanded, all while exhibiting minimal immunogenicity (Le Blanc et al., 2003; Bara et al., 2014). Importantly, BMSC can also differentiate into diverse cell types *in vitro* (Prockop, 1997; Pittenger et al., 1999). These properties make BMSC promising candidates for use in the context of regenerative medicine and other tissue engineering applications (Bianco et al., 2001; Lane et al., 2014).

To date, BMSC and conditioned medium (MSC-CM) have been studied in-depth in the context of wound healing assays in animal skin wound model or diabetic foot ulcers, and have been shown to promote wound repair, neoangiogenesis and to accelerate re-epithelialization. Meanwhile, the regeneration of cutaneous appendages, such as hair follicles and sebaceous glands, were also found. The ability and mechanism of BMSC and MSC-CM to induce the regeneration of hair follicles in mice intradermal injection model, however, remains to be studied in detail.

While genomic and transcriptomic analyses can provide insight into the mechanistic basis for hair follicle regeneration, such mRNA-level data may not align with true phenotypic findings given that protein expression levels are determined by multiple factors including mRNA stability, mRNA localization, protein degradation, and posttranslational modifications. Detailed proteomic analyses are therefore essential in order to fully understand the mechanisms whereby BMSC and MSC-CM influence the growth of hair follicles. Tandem mass spectrometry (MS/MS)-based approaches have emerged as a reliable approach to accurately quantifying relative protein levels in complex samples. The use of isotopomer labels to perform tandem mass tag (TMT) MS/MS analyses is increasingly common (Thompson et al., 2003), offering key advantages including

high sensitivity, good reproducibility, a high signal-to-noise ratio, and the ability to multiplex up to 11 samples.

Herein, we intradermally transplanted BMSC and MSC-CM into mice and then evaluated hair cycle transition, hair follicle regeneration, and HFSC phenotypes. We additionally employed a TMT-based proteomics approach coupled with PRM to better identify key hair regeneration-related protein targets in this therapeutic context.

## MATERIALS AND METHODS

### BMSC Isolation and Culture

Female C57BL/6 mice (4–6 weeks old; Beijing Vital River Laboratory Animal Technology Co., Ltd., China) were euthanized, and BMSC were isolated from the femurs of these animals. After isolation, BMSC were cultured in complete DMEM (Sigma-Aldrich, D6046) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, F2442), 2 mM L-glutamine, and penicillin/streptomycin at 37°C in 5% humidified CO<sub>2</sub>. Cells were grown until 80–90% confluent at which time they were passaged. Cells were passaged three times for use in downstream analyses. Supernatants were collected from cells on the fifth day of the third-passage culture, and were used as conditioned media for cell-free MSC-CM assays.

### BMSC *in vitro* Differentiation

BMSC were induced to undergo osteogenesis by treating them with low-glucose DMEM containing 10% FBS, 50 µg/ml ascorbic acid, 100 nM dexamethasone 10 mM β-glycerophosphate, and penicillin/streptomycin. Osteogenic differentiation was assessed by measuring alkaline phosphatase (ALP) activity through an azo coupling approach on day 7 following induction, and via Alizarin red staining on day 21 following induction.

Adipogenesis was induced by treating BMSC with low-glucose DMEM containing 10% FBS, 500 mM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, 200 µM indomethacin, and 10 µM insulin. After three days, this media was exchanged for adipogenic maintenance medium and cells were cultured for one additional day. This process was repeated thrice, after which oil red O staining was performed to evaluate lipid accumulation within these cells.

### CCK-8 Assay

A CCK-8 kit was used to gauge BMSC proliferation. Briefly, cells were plated in 96-well plates (2000/well in 100 µL), and 10 µL of CCK8 reagent was added per well. Plates were then incubated for 2 h at 37°C, after which absorbance (OD) at 450 nm was measured, and growth curves were established by plotting time against OD values.

### Animals

Female C57BL/6 mice (18–20 g, 7 weeks old, Beijing Vital River Laboratory Animal Technology Co., Ltd.) were used for all *in vivo* experiments, which were conducted in accordance with the China Medical University Guidelines for the Care and Use of Laboratory Animals.

## Intradermal Injections

Hair clippers and an electric razor were used to remove hair from the dorsal flank of all 60 mice, which were subsequently randomized into three treatment groups ( $n = 20$  each): a control group, an MSC-CM group, and a BMSC group. Control mice were administered media containing no cells, while mice in the MSC-CM group were administered cell-free MSC-CM, and mice in the BMSC group were administered  $1 \times 10^6$  BMSC in fresh CM. A 250  $\mu$ L total injection volume was used for a mouse, with 16 separate intradermal injections being made on the dorsal skin of treated mice. One injection was made every other day for two weeks in total.

## Histological Analyses

On days 0, 7, 10, and 15 after the initial injection, mice in each group were euthanized and samples of full-thickness dorsal skin were collected, fixed for 24 h with 4% paraformaldehyde (PFA), and paraffin-embedded prior to slicing into 5  $\mu$ m sections that were subjected to hematoxylin and eosin staining (H&E) based upon standard protocols.

Hair follicle length in each section was quantified by randomly selecting three fields of view per section and measuring the follicle length from papilla to epidermis with the ImageJ program. A total of 20 follicles were measured per mouse, with five mice per group being analyzed at each time point.

## Immunofluorescent Staining

The paraffin-embedded 5  $\mu$ m-thick sections prepared above were used for IF staining. Antigen retrieval was first achieved by treating samples for 4 min with citrate buffer at 100°C, followed by blocking for 1 h with 5% BSA at room temperature. Sections were then probed overnight with primary rabbit anti-Krt15 (1:100 dilution, Abcam, ab52816) and anti-Ki67 (1:100 dilution, Novus Biologicals, NBP2-22112) or anti-Sox9 (1:250 dilution, Abcam, ab185966) and anti-Ki67 (1:100 dilution, Novus Biologicals, NBP2-22112) at 4°C, followed by incubation for 1 h with goat anti-rabbit IgG conjugated to AF594 (1:500 dilution, Cell Signaling, #8889) or goat anti-mouse IgG conjugated to AF488 (1:200 dilution, Abcam, ab150113) at room temperature. DAPI was then used to stain cell nuclei, and a Fluoview FV1000 confocal laser scanning fluorescence microscope (Olympus, Tokyo, Japan) was employed to image cells.

## Protein Extraction, Trypsin Digestion, and TMT Proteomic Labeling

A total of four full-thickness dorsal skin samples from each group on day 7 post-injection were collected and subjected to total protein extraction with the MinuteTM Total Protein Extraction Kit for Skin Tissue (Invent Biotechnologies, Inc. Beijing, China). Trypsin digestion was then performed by reducing the protein lysate with a 5 mM dithiothreitol (DTT) solution for 30 min at 56°C, followed by alkylation with 11 mM iodoacetamide (IAA) for 15 min at room temperature protected from light. Next, 200 mM tetraethylammonium bromide (TEAB) was used to dilute samples to a urea concentration of <2 M, and trypsin

was added at a 1:50 trypsin-to-protein mass ratio overnight at 37°C, followed by a second digestion for 4 h at a 1:100 trypsin-to-protein mass ratio. Once digestion was complete, a Strata X C18 SPE column (Phenomenex, CA, United States) was used to achieve protein desalting, and samples were vacuum-dried. These peptides were then resuspended in 0.5 M TEAB and processed with a 6-plex TMT kit (Thermo Fisher Scientific, CA, United States) based on provided directions. Briefly, one unit of TMT reagent, which was required to label 100  $\mu$ g of peptide was thawed and reconstituted in acetonitrile (ACN). The peptide mixtures were then incubated with the prepared TMT reagent for 2 h at room temperature. Finally, TMT-labeled peptide mixtures were pooled, desalted and dried by vacuum centrifugation.


## HPLC Fractionation, LC-MS/MS Analysis, and Database Search

TMT-labeled peptides were fractionated via high pH reverse-phase high-performance liquid chromatography (HPLC) with an Agilent 300Extend C18 column (5  $\mu$ m particles, 4.6 mm ID, 250 mm long). Briefly, TMT-labeled peptide mixture was first separated into 60 fractions with a gradient of 8–32% acetonitrile (ACN, pH 9.0) over 60 min. Then, the fractions were combined into nine fractionated simplified samples and dried by vacuum centrifuging.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed at PTM Biolab Hangzhou (Hangzhou, China). All fragments were dissolved in solvent A (0.1% formic acid and 2% acetonitrile), directly loaded onto a home-made reversed-phase analytical column (15 cm length, 75  $\mu$ m i. d.). The gradient was comprised of an increase from 6 to 23% solvent B (0.1% formic acid in 100% acetonitrile) over 42 min, 23–35% solvent B in 12 min and climbing to 80% solvent B in 3 min. Finally, a holding phase at 80% solvent B for the last 3 min was performed, all at a constant flow rate of 450 nL/min on a NanoElute ultraperformance liquid chromatography (UPLC) system. The peptides were subjected to Capillary source followed by tandem mass spectrometry (MS/MS) in tims-TOF Pro coupled online to the UPLC. The electrospray voltage applied was 2.0 kV and intact peptides were detected in the TOF. The secondary mass spectrometry scan range was from 100 to 1700 m/z. Data collection was acquired in parallel accumulation-serial fragmentation (PASEF) mode. A first mass spectrometry was collected and PASEF mode was used for 10 times to collect the secondary mass spectrometry with the charge of the parent ion in the range of 0–5. The dynamic exclusion was set at 30 s to avoid repeated scanning of parent ions.

The Maxquant search engine (v.1.6.6.0) was used to analyze the resultant data, with MS/MS spectra being searched against the *Mus\_musculus\_10,090* database (17,045 sequences) concatenated with a reverse decoy database. Trypsin/p was specified as cleavage enzyme allowing up to two missing cleavages. The mass tolerance for precursor ions was set as 20 ppm in First search and 5 ppm in Main search, respectively, and 0.02 Da was set for fragment ions. Carbamidomethyl on Cys





was specified as fixed modification and oxidation on Met was specified as variable modifications. FDR was adjusted to <1% and minimum score for peptides was set >40.

### Parallel Reaction Monitoring Analyses

Protein isolation and trypsinization were conducted as above, after which a PRM mass spectrometric analysis was performed via MS/MS with Q Exactive Plus (Thermo) coupled online to the UPLC. The LC parameters, electrospray voltage, scan range, and Orbitrap resolution were identical to those used for TMT analyses. Automatic gain control was set to 3E6 for full MS and 1E5 for MS/MS, with a maximum IT of 20 ms for full MS and auto for MS/MS. An MS/MS isolation window of 2.0 m/z was used, and the resultant MS data were analyzed with Skyline (v.3.6). Peptide settings: enzyme was set as Trypsin [KR/P], Max missed cleavage set as 2. The peptide length was set as 8–25, Variable modification was set as Carbamidomethyl on Cys and oxidation on Met, and max variable modifications was set as 3. Transition settings: precursor charges were set as 2, 3, ion charges were set as 1, 2, ion types were set as b, y, p. The product ions were set as from ion three to last ion, the ion match tolerance was set as 0.02 Da.

### Bioinformatics Analyses

DEPs were subjected to functional annotation based upon Gene Ontology (GO) classifications, subcellular localization, and COG/KOG categories, using the UniProt-GOA database and InterProScan, Wolfpsort, and the COG/KOG database.

The enrichment of DEPs for particular GO terms, KEGG pathways, and protein domains were assessed using the GO

annotations, KEGG, and InterPro databases, respectively, using two-tailed Fisher's exact test with a  $p < 0.05$  as the threshold of significance.

A protein-protein interaction (PPI) network incorporating identified DEPs was prepared with the STRING database (<https://string-db.org>), using a score >0.4 as the significance threshold for identified interactions.

### Statistical Analysis


Data are means  $\pm$  SD from three or more experiments, and were compared via one- or two-way ANOVAs with Tukey's test.  $p < 0.05$  was the significance threshold.

## RESULTS

### BMSC Characterization

Cultured BMSC exhibit a normal round morphology when cultured at  $10^6$  cells/mL. Within 24–48 h of isolation, these cells began to adhere and form radial colonies that were evident within 5 days, growing to 80–90% confluence within 7 days. At the end of this 7-day period, cells exhibited polygonal, triangular, and spindle-like morphology, and were subsequently passaged. Remaining erythrocytes and other non-adherent cells were removed by repeatedly changing the media and passaging these cells, and BMSC from the third passage exhibited uniform fibroblast-like spindle-shaped morphology and were considered suitable for *in vivo* use (Figure 1A).

To explore the ability of these BMSC to undergo osteogenesis *in vitro*, they were treated with osteogenic differentiation



**FIGURE 2** | Macroscopic and histologic assessment of mice on 0, 7, 10, 15 days after intradermally injection of MSC-CM and BMSC **(A)** The dorsal skin of control, MSC-CM treated and BMSC treated mice was photographed on 0, 7, 10, and 15 days **(B)** Schematic representation of injection sites and photos of mouse after injection **(C)** Quantification of area of hair regrowth. values are represented in percentage. \* $p < 0.05$ , \*\* $p < 0.01$  **(D)** Representative H&E staining images of dorsal skin sections on 0, 7, 10, and 15 days for determination of hair follicle cycle and length. Scale bar: 200  $\mu\text{m}$  **(E)** Graph represents length of hair follicle of the visible microscopic field (at-least three fields) with 20 measurements was taken in all three groups. Values are represented in  $\mu\text{m}$ . Data are expressed as mean  $\pm$  SD. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .


medium and ALP staining was conducted after 7 days via the azo coupling approach, revealing positively stained (blue-purple) cytoplasmic precipitates. Furthermore, Alizarin red staining was used to confirm the differentiation of these cells based on the presence of calcium nodules and bone mineralization on day 21 (**Figure 1B**). We also determined that these BMSC were able to differentiate into adipocytes, as evidenced by the presence of lipid droplets within 4 days and the presence of clear lipid vacuoles upon oil red O staining on day 12 of the differentiation process (**Figure 1C**).

Overall, these findings thus confirmed that these isolated cells were functionally and morphologically consistent with BMSC, making them ideal for use in our experimental model system.

### BMSC Growth Kinetics

A CCK-8 assay was next used to evaluate the growth kinetics of third-passage BMSC, revealing a standard “S”-shaped curve with a lag phase from days 1–3, followed by logarithmic growth from days 3–6, a plateau beginning on day 6, and a slight decrease in cell numbers beginning on day 8 (**Figure 1D**). Based upon this





curve, we elected to utilize third-passaged BMSC collected on the fifth day of culture for all intradermal injection experiments.

## The Impact of BMSC and MSC-CM on Hair Follicle Transition *in vivo*


For C57BL/6 mice, shaved skin typically appears pink during the telogen stage but darkens upon anagen initiation (Sato et al., 1999). All mice appeared to be in the telogen phase prior to injection. On day 7 post-injection, however, dark punctate spots were evident in the skin of mice in the BMSC and MSC-CM treatment groups but not in control animals. On day 10 post-injection, the majority of mice in the BMSC and MSC-CM treatment groups had entered the anagen phase, with the tips of hair shafts having begun to emerge from the epidermal layer and with dorsal pigmentation having increased substantially in both groups, with some darkening beginning to appear in the control group as well. On day 15 post-injection, hair growth was nearly complete in the BMSC group, and the majority of the dorsal skin of MSC-CM-treated mice was dark, whereas in control mice this pigmentation and hair growth was sporadic and uneven (**Figure 2A**). The schematic representation of injection sites and photos of mouse after injection were shown in **Figure 2B**. Together, these data revealed that BMSC and MSC-CM treatment were sufficient to induce hair cycle transition in mice. Quantification of these data confirmed that BMSC treatment significantly enhanced hair growth relative to control treatment on days 7, 10, and 15 post-treatment ( $*p < 0.05$ ,  $**p < 0.01$ ) (**Figure 2C**).

## Histopathological Staining


We next conducted the H&E staining of tissue samples from these mice, which revealed that samples of control, MSC-CM and BMSC groups were all in telogen on day 0. On day 7 post-injection, control group samples were still in the telogen phase, whereas BMSC- and MSC-CM-treated samples had entered the anagen phase and exhibited increased numbers of hair matrix cells. On day 10 post-injection, control group samples exhibited an increase in the volume of the hair follicle dermal papilla, while the dermal papilla in the MSC-CM-treated samples was largely surrounded by hair matrix cells, and was surrounded by dermal papilla in the BMSC-treated samples with clear evidence of hair shaft development. On day 15 post-injection, most follicles in the control group had entered the anagen phase, while there was a clear increase in hair follicle density in the BMSC group and the BMSC-CM group (**Figure 2D**). Quantitative analyses confirmed that hair follicle length increased over time after injection, with significantly longer hair follicles being observed in the BMSC and MSC-CM treatment groups relative to the control group ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ) (**Figure 2E**).

## BMSC and MSC-CM Treatments Induce HFSC Activation

HFSCs are key mediators of hair regeneration, and their ability to proliferate is closely linked to hair follicle transition and overall hair growth. As such, we next analyzed the expression of the HFSC markers Krt15 and Sox9 in the dorsal skin of our treated mice via IF staining. This approach revealed that there was no difference in the fluorescence intensity between three groups on




**FIGURE 4 |** Functional annotations and classification of the DEPs in BMSC/Control group and MSC-CM/Control group **(A)** Statistics and volcano plots of the DEPs **(B)** Statistical distribution chart of the DEPs under each GO category (second Level) **(C)** Subcellular localization chart of the DEPs **(D)** COG/KOG functional classification chart of the DEPs. Note: DEPs: Differentially Expressed Proteins.



days 0 and there were significantly more Krt15 + proliferating cells in the bulge region and Ki67 + proliferating cells in the bulb area and infundibulum of hair follicles in the BMSC and MSC-CM treatment groups on days 7, 10, and 15 of treatment relative to the control group (Figure 3A). We also detected a significant increase

in Sox9 expression in the bulge and outer root sheath (ORS) region and Ki67 expression in the bulb area and infundibulum of follicles from BMSC- and MSC-CM-treated mice (Figure 3B). Together, these data show that treatment with BMSC or MSC-CM can trigger HFSC activation and thereby promote hair regrowth.





**FIGURE 6** | Discovery of candidate hair follicle regeneration related proteins **(A)** Venn diagrams of differentially expressed proteins between BMSC vs. control and MSC-CM vs. control groups. Fold change >1.85 or <0.54 and  $p$ -value < 0.05 **(B)** Heatmap of the 60 optimized DEPs in the Control, MSC-CM, and BMSC groups. The X-coordinate stands for the DEPs, while Y-coordinate stands for the different groups.

## Identification of Proteins Differentially Expressed in Response to BMSC and MSC-CM Treatment

We next conducted a TMT labeling-based proteomic analysis of dorsal skin samples from mice in our control, BMSC, and MSC-CM treatment groups. In total, we identified 63,131 peptides, of which 60,598 were unique, leading to the identification of 5,046 quantifiable proteins. Those proteins with a fold change (FC) > 1.30 or <0.77 and  $p < 0.05$  when comparing the BMSC or MSC-CM groups to the control group were identified as differentially expressed proteins (DEPs).

In total, we identified 1,060 DEPs when comparing the BMSC and control group samples (638 upregulated, 422 downregulated), while 770 were identified when comparing the MSC-CM and control group samples (511 upregulated, 259 downregulated) (**Figure 4A**).

In the BMSC vs. control and MSC-CM vs. control groups, overall DEPs were classified based upon their enrichment in specific GO biological process (BP), molecular function (MF), and cellular component (CC) terms. With respect to BPs, DEPs were primarily involved in cellular processes (899 proteins; 648 proteins), biological regulation (728 proteins; 506 proteins), and metabolic processes (661 proteins; 496 proteins). With respect to CCs, these DEPs were primarily enriched in cell (970 proteins; 709 proteins), organelle (816 proteins; 590 proteins), and membrane-enclosed lumen (480 proteins; 358 proteins). With respect to MFs, DEPs were mainly enriched for binding (730 proteins; 514 proteins),

catalytic activity (382 proteins; 273 proteins), and molecular function regulation (110 proteins; 66 proteins) (**Figure 4B**).

Wolfpsort was used to predict the subcellular localization of these DEPs, which were primarily localized to the nucleus (30.78%; 33.51%), cytoplasm (29.18%; 28.83%), and extracellular compartment (14.26%; 11.82%) (**Figure 4C**).

COG/KOG functional classification analyses assigned these DEPs to 23 functional KOG classifications that were primarily associated with signal transduction (117 proteins; 72 proteins), translation, ribosomal structure, and biogenesis (97 proteins; 73 proteins), and transcription (91 proteins; 68 proteins) (**Figure 4D**).

## Functional Enrichment Analyses of Treatment-Related DEPs

To better understand the relationship between identified DEPs and hair regrowth, we next conducted functional enrichment analyses of proteins that were differentially expressed between the BMSC or MSC-CM groups and the control group based upon GO, KEGG pathway, and protein domain analyses.

With respect to GO biological processes, DEPs were enriched in the regulation of gene expression, regulation of cellular biosynthetic processes, and negative regulation of gene expression. They were additionally enriched for cellular components including the nuclear lumen, nuclear part, and nucleoplasm, and for molecular functions including nucleic

**TABLE 1 |** The 50 optimized up-regulated expressed proteins.

| Protein ID | Protein name  | Gene name | Fold change (BMSCs/control) | p-value (BMSCs/control) | Fold change (mscs-cm/control) | p-value (mscs-cm/control) |
|------------|---|-----------|-----------------------------|-------------------------|-------------------------------|---------------------------|
| A2A5X5     | Keratin-associated protein 16-1                     | Krtap16-1 | 31.561                      | 3.03E-03                | 12.86                         | 3.92E-02                  |
| Q9Z320     | Keratin, type I cytoskeletal 27                     | Krt27     | 7.373                       | 4.80E-03                | 4.436                         | 1.46E-02                  |
| Q8VCW2     | Keratin, type I cytoskeletal 25                     | Krt25     | 6.192                       | 2.77E-03                | 5.027                         | 7.05E-03                  |
| Q9Z185     | Protein-arginine deiminase type-1                   | Padl1     | 5.635                       | 3.89E-03                | 5.357                         | 1.04E-03                  |
| A6BLY7     | Keratin, type I cytoskeletal 28                     | Krt28     | 5.455                       | 1.45E-02                | 3.406                         | 3.25E-02                  |
| P07147     | 5,6-Dihydroxyindole-2-carboxylic acid oxidase       | Tyrp1     | 4.899                       | 1.91E-02                | 5.007                         | 1.92E-02                  |
| Q80V42     | Carboxypeptidase M                                  | Cpm       | 4.572                       | 2.74E-03                | 2.833                         | 1.26E-02                  |
| P29812     | L-dopachrome tautomerase                            | Dct       | 4.457                       | 1.73E-05                | 3.564                         | 1.64E-04                  |
| Q9QXD6     | Fructose-1,6-bisphosphatase 1                       | Fbp1      | 4.31                        | 1.53E-03                | 2.421                         | 4.01E-02                  |
| Q09143     | High affinity cationic amino acid transporter 1     | Slc7a1    | 3.674                       | 1.24E-02                | 2.487                         | 3.50E-02                  |
| P02798     | Metallothionein-2                                   | Mt2       | 3.479                       | 1.81E-04                | 2.281                         | 8.23E-03                  |
| Q8R100     | Calcium homeostasis modulator protein 5             | Calhm5    | 3.469                       | 2.35E-02                | 2.506                         | 4.53E-02                  |
| Q6P5F6     | Zinc transporter ZIP10                              | Slc39a10  | 3.342                       | 1.39E-03                | 3.357                         | 4.21E-03                  |
| Q6NS46     | Protein RRP5 homolog                                | Pdcd11    | 3.295                       | 3.84E-02                | 2.426                         | 9.72E-03                  |
| O70433     | Four and a half LIM domains protein 2               | Fhl2      | 3.118                       | 9.26E-05                | 2.224                         | 9.31E-04                  |
| P53564     | Homeobox protein cut-like 1                         | Cux1      | 3.062                       | 5.87E-03                | 2.587                         | 1.01E-05                  |
| Q8CEZ4     | Protein mab-21-like 4                               | Mab21l4   | 3.039                       | 1.93E-03                | 2.685                         | 2.16E-03                  |
| Q80 × 72   | Leucine-rich repeat-containing protein 15           | Lrrc15    | 3.02                        | 4.49E-05                | 3.42                          | 7.61E-05                  |
| O89094     | Caspase-14  | Casp14    | 3.016                       | 1.71E-04                | 2.303                         | 1.84E-03                  |
| P70698     | CTP synthase 1                                      | Ctps1     | 2.984                       | 1.16E-04                | 1.981                         | 2.51E-02                  |
| Q62394     | Zinc finger protein 185                             | Znf185    | 2.764                       | 5.70E-04                | 1.883                         | 1.09E-02                  |
| Q8VDF2     | E3 ubiquitin-protein ligase UHRF1                   | Uhrf1     | 2.619                       | 2.69E-03                | 2.57                          | 1.46E-03                  |
| Q08189     | Protein-glutamine gamma-glutamyltransferase E       | Tgm3      | 2.614                       | 5.94E-03                | 1.854                         | 3.75E-02                  |
| P11088     | Filaggrin (fragment)                                | Flg       | 2.587                       | 5.12E-03                | 2.896                         | 3.02E-03                  |
| Q91WT9     | Cystathionine beta-synthase                         | Cbs       | 2.47                        | 5.79E-03                | 1.931                         | 3.65E-02                  |
| Q3UNX5     | Acyl-coenzyme a synthetase ACSM3, mitochondrial     | Acsm3     | 2.459                       | 4.44E-02                | 3.024                         | 2.87E-02                  |
| Q9Z184     | Protein-arginine deiminase type-3                   | Padl3     | 2.384                       | 2.05E-02                | 2.078                         | 1.38E-02                  |
| P11440     | Cyclin-dependent kinase 1                           | Cdk1      | 2.359                       | 1.04E-03                | 2.308                         | 8.70E-04                  |
| P07607     | Thymidylate synthase                                | Tyms      | 2.327                       | 6.90E-03                | 2.11                          | 2.64E-02                  |
| O08740     | DNA-directed RNA polymerase II subunit RPB11        | Polr2j    | 2.298                       | 7.26E-03                | 2.125                         | 8.61E-03                  |
| Q9D7Z7     | Ly6/PLAUR domain-containing protein 5               | Lypd5     | 2.255                       | 3.05E-02                | 2.055                         | 3.75E-02                  |
| Q8C156     | Condensin complex subunit 2                         | Ncaph     | 2.211                       | 6.54E-03                | 1.908                         | 3.10E-02                  |
| P54227     | Stathmin OS = <i>Mus musculus</i>                   | Stmn1     | 2.209                       | 8.55E-06                | 2.219                         | 3.69E-04                  |
| O88507     | Ciliary neurotrophic factor receptor subunit alpha  | Cntrf     | 2.207                       | 1.66E-02                | 2.102                         | 1.54E-02                  |
| Q9JMG1     | Endothelial differentiation-related factor 1        | Edf1      | 2.16                        | 1.18E-02                | 1.908                         | 2.87E-02                  |
| P16460     | Argininosuccinate synthase                          | Ass1      | 2.114                       | 2.85E-03                | 1.958                         | 9.77E-03                  |
| E9PVX6     | Proliferation marker protein Ki-67                  | Mki67     | 2.091                       | 3.10E-03                | 2.005                         | 4.46E-03                  |
| O0HKG6     | Ribonuclease T2-B                                   | Rnaset2b  | 2.081                       | 3.82E-03                | 1.975                         | 3.23E-02                  |
| Q02614     | SAP30-binding protein                               | Sap30bp   | 2.076                       | 1.55E-03                | 2.116                         | 2.68E-03                  |
| Q8C5N3     | Pre-mRNA-splicing factor CWC22 homolog              | Cwc22     | 2.006                       | 4.81E-02                | 2.492                         | 1.23E-02                  |
| Q60928     | Glutathione hydrolase 1 proenzyme                   | Ggt1      | 2.005                       | 1.64E-02                | 2.247                         | 1.99E-02                  |
| Q9CXU9     | Eukaryotic translation initiation factor 1 b        | Eif1b     | 2.003                       | 2.29E-02                | 2.093                         | 4.62E-02                  |
| Q5BLK4     | Terminal uridylyltransferase 7                      | Tut7      | 2.002                       | 6.58E-03                | 1.924                         | 6.56E-03                  |
| Q99MD9     | Nuclear autoantigenic sperm protein                 | Nasp      | 1.991                       | 2.30E-03                | 2.022                         | 2.47E-03                  |
| Q80XN0     | D-beta-hydroxybutyrate dehydrogenase, mitochondrial | Bdh1      | 1.962                       | 2.41E-02                | 2.199                         | 1.16E-02                  |
| Q9Z2D8     | Methyl-CpG-binding domain protein 3                 | Mbd3      | 1.959                       | 1.27E-02                | 1.926                         | 1.73E-02                  |
| Q8K2Z4     | Condensin complex subunit 1                         | Ncapd2    | 1.951                       | 1.92E-04                | 1.93                          | 5.00E-04                  |
| Q8R1H0     | Homeodomain-only protein                            | Hopx      | 1.926                       | 1.61E-02                | 1.858                         | 1.23E-02                  |
| Q3THJ3     | Probable RNA-binding protein EIF1AD                 | Eif1ad    | 1.881                       | 1.54E-02                | 2.096                         | 1.14E-02                  |
| P25206     | DNA replication licensing factor MCM3               | Mcm3      | 1.858                       | 1.51E-03                | 1.955                         | 7.45E-04                  |

acid binding, heterocyclic compound binding, and organic cyclic compound binding (**Figure 5A**).

KEGG pathway enrichment analyses revealed these DEPs to be enriched in DNA replication, mismatch repair, spliceosome, and ribosome pathways (**Figure 5B**).

Protein domain enrichment analyses revealed these DEPs to be enriched in RNA recognition motifs and trypsin domain (**Figure 5C**).

Together, based on functional classifications and enrichment analyses, these DEPs are involved in genetic material replication, cell cycle control, and metabolic regulation, which are related to hair cycle transition.

### PRM Validation

DEPs that were shared between the BMSC vs. control and MSC-CM vs. control datasets ( $FC > 1.85$  or  $< 0.54$  and  $p < 0.05$ ) were identified

**TABLE 2** | The 10 optimized down-regulated expressed proteins.

| Protein ID | Protein name  | Gene name | Fold change (BMSCs/control) | p-value (BMSCs/control) | Fold change (mSCs-cm/control) | p-value (mSCs-cm/control) |
|------------|---|-----------|-----------------------------|-------------------------|-------------------------------|---------------------------|
| Q9WV06     | Ankyrin repeat domain-containing protein 2                      | Ankrd2    | 0.358                       | 1.33E-02                | 0.418                         | 4.21E-02                  |
| Q8K299     | Scavenger receptor class a member 5                             | Scara5    | 0.386                       | 5.30E-04                | 0.437                         | 1.10E-03                  |
| P56392     | Cytochrome c oxidase subunit 7A1, mitochondrial                 | Cox7a1    | 0.399                       | 1.68E-02                | 0.447                         | 2.00E-02                  |
| P52850     | Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 | Ndst2     | 0.428                       | 1.64E-02                | 0.352                         | 1.18E-02                  |
| P04247     | Myoglobin   | Mb        | 0.473                       | 2.13E-02                | 0.482                         | 1.72E-02                  |
| P35385     | Heat shock protein beta-7                                       | Hspb7     | 0.487                       | 7.50E-03                | 0.53                          | 7.28E-03                  |
| P50136     | 2-Oxoisovalerate dehydrogenase subunit alpha, mitochondrial     | Bckdha    | 0.489                       | 4.80E-02                | 0.396                         | 3.00E-02                  |
| P22437     | Prostaglandin G/H synthase 1                                    | Ptgs1     | 0.49                        | 2.22E-02                | 0.499                         | 1.93E-02                  |
| O55013     | Trafficking protein particle complex subunit 3                  | Trappc3   | 0.503                       | 3.45E-02                | 0.499                         | 2.09E-02                  |
| P70695     | Fructose-1,6-bisphosphatase isozyme 2                           | Fbp2      | 0.51                        | 1.29E-03                | 0.531                         | 3.51E-03                  |

using Venn diagrams, leading to the identification of 60 optimized DEPs, of which 50 and 10 were up- and down-regulated, respectively (Figure 6A; Tables 1, 2). These proteins are shown in a heatmap in Figure 6B. Of these 60 DEPs, we selected nine upregulated DEPs (Krt25, Cpm, Ctps1, Flg, Ncapd2, Tyrp1, Dct, Tgm3, Stmn1) (Figures 7A,B) and five downregulated DEPs (Mb, Hspb7, Cox7a1, Scara5, Fbp2) (Figure 7C) for subsequent PRM validation. Our quantitative PRM results confirmed that these candidate DEPs exhibited trends comparable to those observed upon TMT analysis, confirming the reliability of our proteomics data (Table 3).

## PPI Network Analysis

Lastly, we constructed a PPI network incorporating DEPs that were shared between the BMSC vs. control and MSC-CM vs. control datasets, including some of the proteins from our PRM validation analysis. Several of our PRM validation proteins were identified as hub proteins within this PPI network, including Stathmin 1 (Stmn1), Non-SMC condensin I complex subunit D2 (Ncapd2), Keratin, type I cytoskeletal 25 (Krt25), and Cytidine triphosphate synthetase 1 (Ctps1) (Figure 8). These proteins may thus play key roles in mitosis and migration, stem cell proliferation, hair follicle regeneration, and hair cycle transition.

## DISCUSSION

BMSC and derivatives thereof are frequently studied as a potential resource for use in therapeutic applications as a means of repairing damaged tissue (Zhang et al., 2018), treating inflammatory diseases (Shi et al., 2018; Harrell et al., 2019), or normalizing aberrant immunological and inflammatory responses in a range of contexts. BMSC are particularly promising in these therapeutic contexts as they can undergo self-renewal, multipotent differentiation, and enable patient-specific tissue regeneration without any significant ethical concerns (Park et al., 2019).

Significant progress has been made in applying BMSC and conditioned medium as a means of treating androgenic alopecia and alopecia areata (Elmaadawi et al., 2018). BMSC-conditioned medium collected during BMSC culture has been


used as a cell-free therapeutic approach in stem cell therapy. Paracrine factors including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), and platelet-derived growth factor (PDGF) are present in MSC-CM preparations and are likely to contribute to tissue follicle regeneration (Fu et al., 2019).

The mechanisms whereby BMSC can facilitate hair regeneration, however, remain poorly understood. As such, in the present study, we injected BMSC and MSC-CM into the dorsal side of 7-week-old C57BL/6 mice and explored the biological basis of BMSC-induced hair regrowth. We confirmed that both of these treatment approaches were able to expedite the telogen-to-anagen transition necessary to enhance hair growth.

Hair loss can be classified as being either permanent, cicatricial, non-reversible scarring alopecia, or temporary, non-cicatricial, reversible non-scarring alopecia. In cases of scarring alopecia, as in patients with cutaneous lupus erythematosus and lichen planus, inflammation leads to irreversible HFSC loss. In contrast, forms of non-scarring alopecia such as alopecia areata (AA) and androgenic alopecia (AGA) are characterized by the loss of progenitor cells but the preservation of HFSCs, allowing for the restoration of hair growth (Garza et al., 2011). Promoting the proliferation and differentiation of HFSCs is thus necessary to facilitate hair regeneration and telogen-to-anagen transition. Several signaling pathways regulate HFSCs activation and they include Wnt/ $\beta$ -catenin (Deschene et al., 2014), BMP, and mTOR (Deng et al., 2015) signaling pathways.


HFSCs are activated via a two-step process during hair regeneration: Secondary hair germ cells are first activated by dermal papilla at anagen onset, followed by bulge HFSC during the anagen III phase (Greco et al., 2009). Cytokeratin 15 (Krt15) is an HFSC marker protein (Lyle et al., 1998; Liu et al., 2003), and is used together with CD200 and CD34 to monitor the efficacy of AA and AGA treatment (Elmaadawi et al., 2018). Sox9 (Vidal et al., 2005; Nowak et al., 2008) is also a potential HFSC marker. Herein, we found that the levels of Krt15- and Sox9-positive cells rose in bulge and ORS regions following BMSC and MSC-CM injection, confirming that these treatments were able to induce





**TABLE 3** | PRM analysis of 14 candidate proteins.

| Protein ID | Protein name                                    | Gene name | Peptide sequence                        | BMSCs/<br>Control<br>Ratio | BMSCs/<br>Control<br>ratio (TMT) | MSCs-CM/<br>Control Ratio | MSCs-CM/<br>Control<br>Ratio (TMT) |
|------------|---|-----------|---|----------------------------|----------------------------------|---------------------------|------------------------------------|
| Q8VCW2     | Keratin, type I cytoskeletal 25                 | Krt25     | LASYLDNVQALQEANADLEQK<br>LEYEQLLNVK     | ∞                          | 6.19                             | ∞                         | 5.03                               |
| P07147     | 5,6-Dihydroxyindole-2-carboxylic acid oxidase   | Tyrp1     | NTVEGYSAPTGK                            | ∞                          | 4.90                             | ∞                         | 5.01                               |
| P29812     | L-dopachrome tautomerase                        | Dct       | EQFLGALDLAK                             | ∞                          | 4.46                             | ∞                         | 3.56                               |
| Q80V42     | Carboxypeptidase M                              | Cpm       | LPLFWNDNK                               | 7.51                       | 4.57                             | 6.65                      | 2.83                               |
| P70698     | CTP synthase 1                                  | Ctps1     | GLGLSPDLWCR<br>NVLGWQDANSTEFDPK         | 4.74                       | 2.98                             | 3.24                      | 1.98                               |
| P11088     | Filaggrin (fragment)                            | Flg       | AGSSSGSGVQGASAGGLAADASR<br>GQSPDASGR    | 3.42                       | 2.59                             | 5.66                      | 2.90                               |
| P54227     | Stathmin  | Stmn1     | ASGQAFELISPR<br>ESVPDFPLSPPK            | 2.79                       | 2.21                             | 2.92                      | 2.22                               |
| Q08189     | Protein-glutamine gamma-glutamyltransferase E   | Tgm3      | VITNFNSAHDTR<br>IAYSQYER                | 2.87                       | 2.61                             | 1.80                      | 1.85                               |
| Q8K2Z4     | Condensin complex subunit 1                     | Ncapd2    | HSQELSSILDDAALSGSDR<br>GFAAFLTELAER     | 2.34                       | 1.95                             | 2.22                      | 1.93                               |
| P04247     | Myoglobin                                       | Mb        | VEADLAGHGQEVLIQGLFK<br>GQHAAEIQLAQSHATK | 0.36                       | 0.47                             | 0.31                      | 0.48                               |
| P35385     | Heat shock protein beta-7                       | Hspb7     | CQLPEDVDPTSVTSALR                       | 0.40                       | 0.49                             | 0.40                      | 0.53                               |
| P56392     | Cytochrome c oxidase subunit 7A1, mitochondrial | Cox7a1    | LFAQDNLDLPVHLK                          | 0.41                       | 0.40                             | 0.62                      | 0.45                               |
| Q8K299     | Scavenger receptor class a member 5             | Scara5    | LLQAPLQADLTEQVWK<br>VGVLGEELADVGGALR    | 0.49                       | 0.39                             | 0.48                      | 0.44                               |
| P70695     | Fructose-1,6-bisphosphatase isozyme 2           | Fbp2      | EAVITAQER<br>VPLILGSPEDVQEYLSVCVQR      | 0.50                       | 0.51                             | 0.46                      | 0.53                               |



telogen-to-anagen hair cycling via promoting HFSC proliferation.

We also found that BMSC and MSC-CM treatment were associated with significant increases in the expression of

certain key hair structure- and induction-related proteins. For example, keratins, which encode intermediate filaments, are involved in several key processes. The type I keratin gene *Krt25* is expressed in the hair medulla and all three layers of the inner root sheath (IRS) (Langbein et al., 2006), wherein it is involved in protecting, supporting, and molding the hair shaft. Ansar (Ansar et al., 2015) and Zernov (Zernov et al., 2016) et al. found that *Krt25* mutations were damaging to intermediate filament formation and hair follicle development, resulting in autosomal recessive hypotrichosis. Moreover, the transglutaminase (TGase) isoform TGase-3 is expressed within the cuticle and cortex of growing hair fibers wherein it is involved in progressive hair shaft scaffolding via driving the formation of isopeptide bonds between intermediate filaments and keratin-associated proteins (KAPs). Tarsca et al. have also shown this enzyme to play a role in regulating mouse anagen hair fiber rigidity (Tarsca et al., 1997), and Sebastien et al. have referred to it as a possible mediator in the context of hair shaft scaffolding (Thibaut et al., 2009). Susan et al. also showed that hair lacking TGase-3 was thinner and that there were clear cuticle cell alterations in mice lacking TGase-3 (John et al., 2012). We also found the expression of the hair melanin biosynthetic proteins 5,6-dihydroxyindole-2-carboxylic acid oxidase (*Tyrp1*) (Zdarsky et al., 1990; Kobayashi et al., 1994) and L-dopachrome tautomerase (*Dct*) (Jackson et al., 1992; Tsukamoto et al., 1992) to be significantly increased in skin samples following BMSC and MSC-CM treatment.

Many studies have shown T cells and macrophages to be recruited and to induce hair regeneration via the activation of

HFSC differentiation (Rahmani et al., 2020) during physiologic hair cycling (Castellana et al., 2014; Ali et al., 2017), wounding, and depilation-induced hair growth (Chen et al., 2015; Lee et al., 2017; Wang et al., 2017; Rahmani et al., 2018). Notably, one of our validated DEPs identified in this study, carboxypeptidase M (Cpm), is often used as a marker for the differentiation of monocytes into macrophages (Rehli et al., 1995; Krause et al., 1998). We observed significant Cpm upregulation following BMSC and MSC-CM injection, suggesting that such treatment may be involved in macrophage recruitment and consequent anagen onset. We also identified cytidine triphosphate (CTP) synthetase 1 (Ctps1) to be significantly upregulated in this experimental system, which is noteworthy given that it is involved in activated T cell proliferation (Martin et al., 2014). Our data thus suggested that BMSC and MSC-CM treatment induce hair follicle regeneration through mechanisms associated with immunomodulation.

We additionally identified multiple upregulated proteins related to the cell cycle and proliferation. Filaggrin (Flg), for example, is involved in mechanical barrier function in healthy skin, with Salerno et al. having shown melanoma cells to upregulate Flg (Salerno et al., 2016). Leick et al. also successfully knocked out Flg in DM93 human melanoma cells via a CRISPR/Cas9 approach and thereby clarified its role in the context of cellular growth (Leick et al., 2019). Stathmin 1 (Stmn1) is a protein involved in destabilizing microtubules that it is involved in mitosis and migration by controlling free tubulin dimer availability within cells (Ringhoff and Cassimeris, 2009). Stmn1 depletion has been shown to contribute to cell cycle arrest (Chen et al., 2007) and enhanced apoptotic death (Alli et al., 2007; Ma et al., 2017). Bichsel et al. also previously demonstrated that Stmn1 deletion promoted expedited catagen transition and prematurely suppressed follicular proliferation, suggesting it plays a critical role in hair follicle cycling (Bichsel et al., 2016). Non-SMC condensin I complex subunit D2 (Ncapd2) is a condensin I complex subunit encoded on chromosome 12p13.3 that is primarily involved in chromosome condensation and segregation. Zhang et al. determined that Ncapd2 is an essential mediator of cell cycle progression and triple-negative breast cancer (TNBC) cell migration such that when it was knocked down, TNBC cells failed to proliferate or exhibit invasive activity, and instead underwent apoptotic death (Zhang et al., 2020).

In addition to these upregulated proteins, we also validated multiple proteins that were downregulated in the BMSC and MSC-CM groups relative to control mice (Hspb7, Mb, Cox7a1, Fbp2, Scara5). Hspb7, Mb, Cox7a1, Fbp2, and Scara5 have all previously been identified as tumor suppressor genes (Naderi, 2018) in breast cancer (Braganza et al., 2019), non-small cell lung cancer (Zhao et al., 2019), gastric cancer (Li et al., 2013), sarcoma (Huangyang et al., 2020), and hepatocellular carcinoma (Huang et al., 2010), wherein they can suppress tumor cell invasion, proliferation, and migration. In contrast, our data suggest that BMSC and MSC-CM treatment can enhance proliferation and hair follicle regeneration via reducing the expression of these key proteins.

## CONCLUSION

In summary, we herein evaluated the ability of BMSC and MSC-CM to promote the regeneration of hair follicles. We found that both of these treatments were capable of promoting follicle telogen-to-anagen transition in C57BL/6 mice, increasing follicle length and driving HFSC proliferation. Our TMT-based proteomics approach identified Krt25, Cpm, Stmn1, and Mb as candidate follicle regeneration-related proteins, and these findings were validated via PRM. Overall, these data thus suggest that BMSC and MSC-CM may represent ideal therapeutic approaches to anagen induction and hair growth stimulation as a means of treating HL.

## DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ **Supplementary material**.

## ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of the China Medical University.

## AUTHOR CONTRIBUTIONS

CZ carried out all the experiments, collection and analysis of data, and wrote the manuscript. HC, and XX performed experimental guidance and data analysis. YL, JQ, CY, and GM contributed to BMSC culture and data collection. All authors read and approved the final manuscript.

## FUNDING

This work was supported by the National Natural Science Foundation of China (81972956), the National Key Research and Development Program of China (No.2016YFC0901504) and the 111 Project (D18011).

## ACKNOWLEDGMENTS

The authors would like to thank all the reviewers who participated in the review and MJEditor ([www.mjeditor.com](http://www.mjeditor.com)) for its linguistic assistance during the preparation of this manuscript.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2021.658040/full#supplementary-material>.



## REFERENCES

- Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H.-A., Lai, K., et al. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. *Cell* 169 (6), 1119. doi:10.1016/j.cell.2017.05.002
- Alli, E., Yang, J.-M., and Hait, W. N. (2007). Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. *Oncogene* 26 (7), 1003–1012. doi:10.1038/sj.onc.1209864
- Ansar, M., Raza, S. I., Lee, K., Irfanullah, S., Shahi, A., Dai, H., et al. (2015). A homozygous missense variant in type I keratinKRT25causes autosomal recessive woolly hair. *J. Med. Genet.* 52 (10), 676–680. doi:10.1136/jmedgenet-2015-103255
- Bara, J. J., Richards, R. G., Alini, M., and Stoddart, M. J. (2014). Concise review: bone marrow-derived mesenchymal stem cells change phenotype following *in vitro* culture: implications for basic research and the clinic. *Stem Cells* 32 (7), 1713–1723. doi:10.1002/stem.1649
- Bianco, P., Riminucci, M., Gronthos, S., and Robey, P. G. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 19 (3), 180–192. doi:10.1634/stemcells.19-3-180
- Bichsel, K. J., Hammiller, B., Trempus, C. S., Li, Y., and Hansen, L. A. (2016). The epidermal growth factor receptor decreases Stathmin 1 and triggers catagen entry in the mouse. *Exp. Dermatol.* 25 (4), 275–281. doi:10.1111/exd.12921
- Blanpain, C., Lowry, W. E., Geoghegan, A., Polak, L., and Fuchs, E. (2004). Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. *Cell* 118 (5), 635–648. doi:10.1016/j.cell.2004.08.012
- Braganza, A., Quesnelle, K., Bickta, J., Reyes, C., Wang, Y., Jessup, M., et al. (2019). Myoglobin induces mitochondrial fusion, thereby inhibiting breast cancer cell proliferation. *J. Biol. Chem.* 294 (18), 7269–7282. doi:10.1074/jbc.RA118.006673
- Castellana, D., Paus, R., and Perez-Moreno, M. (2014). Macrophages contribute to the cyclic activation of adult hair follicle stem cells. *Plos Biol.* 12 (12), e1002002. doi:10.1371/journal.pbio.1002002
- Chacón-Martínez, C. A., Klose, M., Niemann, C., Glauche, I., and Wickström, S. A. (2017). Hair follicle stem cell cultures reveal self-organizing plasticity of stem cells and their progeny. *EMBO J.* 36 (2), 151–164. doi:10.15252/embj.201694902
- Chen, C.-C., Wang, L., Plikus, M. V., Jiang, T. X., Murray, P. J., Ramos, R., et al. (2015). Organ-level quorum sensing directs regeneration in hair stem cell populations. *Cell* 161 (2), 277–290. doi:10.1016/j.cell.2015.02.016
- Chen, Y., Lin, M. C., Yao, H., Wang, H., Zhang, A.-Q., Yu, J., et al. (2007). Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. *Hepatology* 46 (1), 200–208. doi:10.1002/hep.21668
- Cotsarelis, G., and Millar, S. E. (2001). Towards a molecular understanding of hair loss and its treatment. *Trends Mol. Med.* 7 (7), 293–301. doi:10.1016/s1471-4914(01)02027-5
- Cotsarelis, G., Sun, T.-T., and Lavker, R. M. (1990). Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. *Cell* 61 (7), 1329–1337. doi:10.1016/0092-8674(90)90696-c
- Deng, Z., Lei, X., Zhang, X., Zhang, H., Liu, S., Chen, Q., et al. (2015). mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration. *J. Mol. Cell Biol.* 7 (1), 62–72. doi:10.1093/jmcb/mjv005
- Deschene, E. R., Myung, P., Rompolas, P., Zito, G., Sun, T. Y., Taketo, M. M., et al. (2014). -Catenin activation regulates tissue growth non-cell autonomously in the hair stem cell niche. *Science* 343 (6177), 1353–1356. doi:10.1126/science.1248373
- Elmaadawi, I. H., Mohamed, B. M., Ibrahim, Z. A. S., Abdou, S. M., El Attar, Y. A., Youssef, A., et al. (2018). Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. *J. Dermatol. Treat.* 29 (5), 431–440. doi:10.1080/09546634.2016.1227419
- Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., and Keiliss-Borok, I. V. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. *Transplantation* 17 (4), 331–340. doi:10.1097/00007890-197404000-00001
- Fu, X., Liu, G., Halim, A., Ju, Y., Luo, Q., Song, A. G., et al. (2019). Mesenchymal stem cell migration and tissue repair. *Cells* 8 (8), 784. doi:10.3390/cells8080784
- Garza, L. A., Yang, C.-C., Zhao, T., Blatt, H. B., Lee, M., He, H., et al. (2011). Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. *J. Clin. Invest.* 121 (2), 613–622. doi:10.1172/JCI44478
- Greco, V., Chen, T., Rendl, M., Schober, M., Pasolli, H. A., Stokes, N., et al. (2009). A two-step mechanism for stem cell activation during hair regeneration. *Cell Stem Cell* 4 (2), 155–169. doi:10.1016/j.stem.2008.12.009
- Harrell, C. R., Jovicic, N., Djonov, V., Arsenijevic, N., and Volarevic, V. (2019). Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. *Cells* 8 (12), 1605. doi:10.3390/cells8121605
- Huang, J., Zheng, D.-L., Qin, F.-S., Cheng, N., Chen, H., Wan, B.-B., et al. (2010). Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. *J. Clin. Invest.* 120 (1), 223–241. doi:10.1172/JCI38012
- Huangyang, P., Li, F., Lee, P., Nissim, L., Weljie, A. M., Mancuso, A., et al. (2020). Fructose-1,6-Bisphosphatase 2 inhibits sarcoma progression by restraining mitochondrial biogenesis. *Cel Metab.* 31 (1), 174. doi:10.1016/j.cmet.2019.10.012
- Jackson, I. J., Chambers, D. M., Tsukamoto, K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., et al. (1992). A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. *EMBO J.* 11 (2), 527–535. doi:10.1002/j.1460-2075.1992.tb05083.x
- John, S., Thiebach, L., Frie, C., Mokkaapati, S., Bechtel, M., Nischt, R., et al. (2012). Epidermal transglutaminase (TGase 3) is required for proper hair development, but not the formation of the epidermal barrier. *PLoS One* 7 (4), e34252. doi:10.1371/journal.pone.0034252
- Kobayashi, T., Urabe, K., Winder, A., Jiménez-Cervantes, C., Imokawa, G., Brewington, T., et al. (1994). Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. *EMBO J.* 13 (24), 5818–5825. doi:10.1002/j.1460-2075.1994.tb06925.x
- Krause, S. W., Rehli, M., and Andreesen, R. (1998). Carboxypeptidase M as a marker of macrophage maturation. *Immunol. Rev.* 161, 119–127. doi:10.1111/j.1600-065x.1998.tb01576.x
- Lane, S. W., Williams, D. A., and Watt, F. M. (2014). Modulating the stem cell niche for tissue regeneration. *Nat. Biotechnol.* 32 (8), 795–803. doi:10.1038/nbt.2978
- Langbein, L., Rogers, M. A., Praetzel-Wunder, S., Helmke, B., Schirmacher, P., and Schweizer, J. (2006). K25 (K25irs1), K26 (K25irs2), K27 (K25irs3), and K28 (K25irs4) represent the type I inner root sheath keratins of the human hair follicle. *J. Invest. Dermatol.* 126 (11), 2377–2386. doi:10.1038/sj.jid.5700494
- Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., and Ringdén, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp. Hematol.* 31 (10), 890–896. doi:10.1016/s0301-472x(03)00110-3
- Lee, P., Gund, R., Dutta, A., Pincha, N., Rana, I., Ghosh, S., et al. (2017). Stimulation of hair follicle stem cell proliferation through an IL-1 dependent activation of  $\gamma\delta$ T-cells. *eLife* 6, e28875. doi:10.7554/eLife.28875
- Leick, K. M., Rodriguez, A. B., Melssen, M. M., Benamar, M., Lindsay, R. S., Eki, R., et al. (2019). The barrier molecules junction plakoglobin, filaggrin, and dystonin play roles in melanoma growth and angiogenesis. *Ann. Surg.* 270 (4), 712–722. doi:10.1097/SLA.00000000000003522
- Li, H., Wang, J., Xu, H., Xing, R., Pan, Y., Li, W., et al. (2013). Decreased fructose-1,6-bisphosphatase-2 expression promotes glycolysis and growth in gastric cancer cells. *Mol. Cancer* 12 (1), 110. doi:10.1186/1476-4598-12-110
- Liu, Y., Lyle, S., Yang, Z., and Cotsarelis, G. (2003). Keratin 15 promoter targets putative epithelial stem cells in the hair follicle bulge. *J. Invest. Dermatol.* 121 (5), 963–968. doi:10.1046/j.1523-1747.2003.12600.x
- Lyle, S., Christofidou-Solomidou, M., Liu, Y., Elder, D. E., Albelda, S., and Cotsarelis, G. (1998). The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. *J. Cell Sci.* 111 (Pt 21), 3179–3188.
- Ma, H.-L., Jin, S.-F., Ju, W.-T., Fu, Y., Tu, Y.-Y., Wang, L.-Z., et al. (2017). Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. *J. Exp. Clin. Cancer Res.* 36 (1), 109. doi:10.1186/s13046-017-0575-4

- Martin, E., Palmic, N., Sanquer, S., Lenoir, C., Hauck, F., Mongellaz, C., et al. (2014). CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. *Nature* 510 (7504), 288–292. doi:10.1038/nature13386
- Naderi, A. (2018). SRARP and HSPB7 are epigenetically regulated gene pairs that function as tumor suppressors and predict clinical outcome in malignancies. *Mol. Oncol.* 12 (5), 724–755. doi:10.1002/1878-0261.12195
- Nowak, J. A., Polak, L., Pasolli, H. A., and Fuchs, E. (2008). Hair follicle stem cells are specified and function in early skin morphogenesis. *Cell stem Cell* 3 (1), 33–43. doi:10.1016/j.stem.2008.05.009
- Park, J., Jun, E. K., Son, D., Hong, W., Jang, J., Yun, W., et al. (2019). Overexpression of Nanog in amniotic fluid-derived mesenchymal stem cells accelerates dermal papilla cell activity and promotes hair follicle regeneration. *Exp. Mol. Med.* 51 (7), 1. doi:10.1038/s12276-019-0266-7
- Paus, R. (1998). Principles of hair cycle control. *J. Dermatol.* 25 (12), 793–802. doi:10.1111/j.1346-8138.1998.tb02507.x
- Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science (New York, N.Y.)* 284 (5411), 143–147. doi:10.1126/science.284.5411.143
- Prockop, D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science*. 276 (5309), 71–74. doi:10.1126/science.276.5309.71
- Rahmani, W., Liu, Y., Rosin, N. L., Kline, A., Raharjo, E., Yoon, J., et al. (2018). Macrophages promote wound-induced hair follicle regeneration in a CX3CR1- and TGF- $\beta$ 1-dependent manner. *J. Invest. Dermatol.* 138 (10), 2111–2122. doi:10.1016/j.jid.2018.04.010
- Rahmani, W., Sinha, S., and Biernaskie, J. (2020). Immune modulation of hair follicle regeneration. *Npj Regen. Med.* 5, 9. doi:10.1038/s41536-020-0095-2
- Rehli, M., Krause, S. W., Kreutz, M., and Andreesen, R. (1995). Carboxypeptidase M is identical to the MAX1 antigen and its expression is associated with monocyte to macrophage differentiation. *J. Biol. Chem.* 270 (26), 15644–15649. doi:10.1074/jbc.270.26.15644
- Ringhoff, D. N., and Cassimeris, L. (2009). Stathmin regulates centrosomal nucleation of microtubules and tubulin dimer/polymer partitioning. *MBoC* 20 (15), 3451–3458. doi:10.1091/mbc.E09-02-0140
- Salerno, E. P., Bedognetti, D., Mauldin, I. S., Deacon, D. H., Shea, S. M., Pinczewski, J., et al. (2016). Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. *Oncoimmunology* 5 (12), e1240857. doi:10.1080/2162402X.2016.1240857
- Sato, N., Leopold, P. L., and Crystal, R. G. (1999). Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. *J. Clin. Invest.* 104 (7), 855–864. doi:10.1172/jci7691
- Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., et al. (2018). Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. *Nat. Rev. Nephrol.* 14 (8), 493–507. doi:10.1038/s41581-018-0023-5
- Tarcsa, E., Marekov, L. N., Andreoli, J., Idler, W. W., Candi, E., Chung, S.-I., et al. (1997). The fate of trichohyalin. *J. Biol. Chem.* 272 (44), 27893–27901. doi:10.1074/jbc.272.44.27893
- Thibaut, S., Cavusoglu, N., de Becker, E., Zerbib, F., Bednarczyk, A., Schaeffer, C., et al. (2009). Transglutaminase-3 enzyme: a putative actor in human hair shaft scaffolding? *J. Invest. Dermatol.* 129 (2), 449–459. doi:10.1038/jid.2008.231
- Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., et al. (2003). Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. *Anal. Chem.* 75 (8), 1895–1904. doi:10.1021/ac0262560
- Tsukamoto, K., Jackson, I. J., Urabe, K., Montague, P. M., and Hearing, V. J. (1992). A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPACHrome tautomerase. *EMBO J.* 11 (2), 519–526. doi:10.1002/j.1460-2075.1992.tb05082.x
- Varothai, S., and Bergfeld, W. F. (2014). Androgenetic alopecia: an evidence-based treatment update. *Am. J. Clin. Dermatol.* 15 (3), 217–230. doi:10.1007/s40257-014-0077-5
- Vidal, V. P. I., Chaboissier, M.-C., Lützkendorf, S., Cotsarelis, G., Mill, P., Hui, C.-C., et al. (2005). Sox9 is essential for outer root sheath differentiation and the formation of the hair stem cell compartment. *Curr. Biol.* 15 (15), 1340–1351. doi:10.1016/j.cub.2005.06.064
- Wang, X., Chen, H., Tian, R., Zhang, Y., Drutskaya, M. S., Wang, C., et al. (2017). Macrophages induce AKT/ $\beta$ -catenin-dependent Lgr5+ stem cell activation and hair follicle regeneration through TNF. *Nat. Commun.* 8, 14091. doi:10.1038/ncomms14091
- Zdarsky, E., Favor, J., and Jackson, I. J. (1990). The molecular basis of brown, an old mouse mutation, and of an induced revertant to wild type. *Genetics* 126 (2), 443–449.
- Zernov, N. V., Skoblov, M. Y., Marakhonov, A. V., Shimomura, Y., Vasilyeva, T. A., Kononov, F. A., et al. (2016). Autosomal recessive hypotrichosis with woolly hair caused by a mutation in the keratin 25 gene expressed in hair follicles. *J. Invest. Dermatol.* 136 (6), 1097–1105. doi:10.1016/j.jid.2016.01.037
- Zhang, S., Chuah, S. J., Lai, R. C., Hui, J. H. P., Lim, S. K., and Toh, W. S. (2018). MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. *Biomaterials* 156, 16–27. doi:10.1016/j.biomaterials.2017.11.028
- Zhang, Y., Liu, F., Zhang, C., Ren, M., Kuang, M., Xiao, T., et al. (2020). Non-SMC condensin I complex subunit D2 is a prognostic factor in triple-negative breast cancer for the ability to promote cell cycle and enhance invasion. *Am. J. Pathol.* 190 (1), 37–47. doi:10.1016/j.ajpath.2019.09.014
- Zhao, L., Chen, X., Feng, Y., Wang, G., Nawaz, I., Hu, L., et al. (2019). COX7A1 suppresses the viability of human non-small cell lung cancer cells via regulating autophagy. *Cancer Med.* 8 (18), 7762–7773. doi:10.1002/cam4.2659

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhang, Li, Qin, Yu, Ma, Chen and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.